DCXR and neoplasm: One recent study highlighted lipid-based nanoparticles delivering MYC-targeted siRNAs (such as DCR-MYC) into tumor cells, leading to efficient MYC silencing, potent anti-proliferative effects, and notable reduction of tumor burden in preclinical models (Raza et al., 2023).